No Clear Winner in BMS, Exelixis/Ipsen First-line Renal Cancer Race

 
• By Kevin Grogan
Wrestlers
B-MS and Exelixis/Ipsen's renal cancer drugs are battling to be first-line therapy • Source: Shutterstock

More from Immuno-oncology

More from Anticancer